Peripheral neuropathies are disorders affecting the peripheral nervous system. Among them, Charcot-Marie-Tooth disease is an inherited sensorimotor neuropathy for which no effective treatment exists yet. Research on Charcot-Marie-Tooth disease has been hampered by difficulties in accessing relevant cells, such as sensory and motor neurons, Schwann cells, and myocytes, which interact at the neuromuscular junction, the specialized synapses formed between nerves and skeletal muscles. This review first outlines the various in vivo models and methods used to study neuromuscular junction deficiencies in Charcot-Marie-Tooth disease. We then explore novel in vitro techniques and models, including complex hiPSC-derived cultures, which offer promising isogenic and reproducible neuromuscular junction models. The adaptability of in vitro culture methods, including cell origin, cell-type combinations, and choice of culture format, adds complexity and excitement to this rapidly evolving field. This review aims to recapitulate available tools for studying Charcot-Marie-Tooth disease to understand its pathophysiological mechanisms and test potential therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898049 | PMC |
| http://dx.doi.org/10.1177/20417314241310508 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From in vivo models to in vitro bioengineered neuromuscular junctions for the study of Charcot-Marie-Tooth disease.
J Tissue Eng
March 2025
University of Limoges, NeurIT UR 20218, GEIST Institute, Limoges, France.
Peripheral neuropathies are disorders affecting the peripheral nervous system. Among them, Charcot-Marie-Tooth disease is an inherited sensorimotor neuropathy for which no effective treatment exists yet. Research on Charcot-Marie-Tooth disease has been hampered by difficulties in accessing relevant cells, such as sensory and motor neurons, Schwann cells, and myocytes, which interact at the neuromuscular junction, the specialized synapses formed between nerves and skeletal muscles.
View Article and Find Full Text PDFCharacterization of a novel zebrafish model of -associated Charcot-Marie-Tooth disease type 4B3.
Brain Commun
February 2025
Program for Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
Biallelic loss of expression/function variants in cause the inherited peripheral neuropathy Charcot-Marie-Tooth type 4B3. There is an incomplete understanding of the disease pathomechanism(s) underlying Charcot-Marie-Tooth type 4B3, and despite its severe clinical presentation, currently no disease-modifying therapies. A key barrier to the study of Charcot-Marie-Tooth type 4B3 is the lack of pre-clinical models that recapitulate the clinical and pathologic features of the disease.
View Article and Find Full Text PDFPotential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S.
Mol Ther Nucleic Acids
March 2025
Vanda Pharmaceuticals Inc., Washington, DC 20037, USA.
Immunoglobulin mu-binding protein 2 () pathogenic variants lead to a spectrum of disorders characterized by alpha-motor neuron degeneration. We describe a compound heterozygous patient diagnosed with Charcot-Marie-Tooth disease type 2S with variants in : a pathogenic missense variant acting in with a confirmed intronic cryptic splice site variant. This variant was shown to result in the creation of a new splice acceptor site, loss of reading frame and nonsense-mediated decay.
View Article and Find Full Text PDFA dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X.
Neurotherapeutics
March 2025
Neuroscience Department, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus; Centre for Neuromuscular Disorders and Neuropathology Lab, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
X-linked Charcot-Marie-Tooth disease (CMT1X) is an inherited demyelinating neuropathy caused by loss-of-function mutations in the GJB1 gene, encoding the gap junction protein connexin32 (Cx32). Cx32 plays a critical role in Schwann cell function and myelin formation in the peripheral nervous system. We have developed a gene replacement therapeutic approach using a humanized AAVrh10 vector construct expressing GJB1 under the control of the Schwann cell-specific human myelin protein zero (MPZ) promoter.
View Article and Find Full Text PDFBIN1 reduction ameliorates -related Charcot-Marie-Tooth neuropathy.
Proc Natl Acad Sci U S A
March 2025
Institut de génétique, biologie moléculaire et cellulaire, département de Médecine translationnelle et neurogénétique, INSERM U1258, CNRS UMR7104, Université de Strasbourg, Illkirch 67404, France.
Charcot-Marie-Tooth (CMT) disease, the most common inherited neuromuscular disorder, manifests as progressive muscle weakness and peripheral nerve defects. Dominant mutations in , encoding the large GTPase dynamin 2, result in CMT without any suggested therapeutic strategy. Different dominant mutations in also cause centronuclear myopathy (CNM), and increasing BIN1 (amphiphysin 2), an endogenous modulator of DNM2, rescued CNM in mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!